Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma

Authors: Fearfield, L.A.; Larkin, J.M.G.¹; Rowe, A.²; A'Hern, R.¹; Fisher, C.¹; Francis, N.³; MacKie, R.⁴; McCann, B.⁵; Gore, M.E.¹; Bunker, C.B.²

Source: British Journal of Dermatology, Volume 156, Number 3, March 2007 , pp. 440-447(8)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Summary Background

The incidence of malignant melanoma is increasing worldwide and patients are being diagnosed earlier with thinner primary lesions. Most patients with very thin melanoma (Breslow thickness < 0·76 mm) are cured by surgery but 2-18% relapse locally or with distant metastases. Objectives

The objective of this study was to establish potential new prognostic markers in very thin melanoma. Methods

We identified a group of subjects with relapsing very thin primary cutaneous melanoma and a matched control group who had not relapsed. We investigated the expression of p16, Helix pomatia agglutinin (HPA), CD95 and CD95 ligand (CD95L) by immunohistochemistry on paraffin-embedded tissue sections from the subject group, their subsequent metastases and the control group. Results

Reduced p16 expression was significantly associated with relapse in very thin melanoma (P = 0·0129). Loss of p16 expression was also found in 76% of metastases. There was no significant association between HPA, CD95 or CD95L expression and subsequent relapse. Conclusions

This work is the first to show a significant loss of p16 in relapsing very thin melanoma.

Keywords: biological markers; prognosis; skin neoplasms

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2133.2006.07581.x

Affiliations: 1: Royal Marsden Hospital, Fulham Road, London, U.K. 2: Department of Dermatology, Imperial College School of Medicine (START Laboratories), Chelsea and Westminster Hospital, London, U.K. 3: Department of Histopathology, Charing Cross Hospital, London, U.K. 4: Department of Dermatology, University of Glasgow, Glasgow, U.K. 5: Department of Histopathology, Norfolk and Norwich Hospital, Colney Lane, Norwich, U.K.

Publication date: 2007-03-01

Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages